Re: Our own BKC on the webcast
in response to
by
posted on
Feb 04, 2021 12:53PM
Agreed. Great question BKC, horribly unprepared answer by DM. The company highlighted this LDL-C issue back in November 2019.....DM should not have been blindsided by that question.
I typed in questions that didn't get read:
1) Will there be any renal function endpoints in BETonMACE2?
2) Will the 100 patient COVID-19 trial be all apabetalone treated, or will some of these 100 be standard of care?
BDAZ